Compare Cassava Sciences Inc (FLNA) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ralph Lauren Corp — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Ralph Lauren Corp trades at $388.1 (market cap $22.26B). The key difference: Ralph Lauren Corp is far larger — about 418.9× Cassava Sciences Inc's market cap, and Ralph Lauren Corp pays a 1% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RL | |
|---|---|---|
Market Cap | $53.14M | $22.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $414.25 |
52-Week Low | $1.09 | $283.34 |
Enterprise Value | -$33.43M | $23.21B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Ralph Lauren (RL) trades at $385.13, up 4.38% over the past day, with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from robust fundamentals including 69.87% gross margins and 34.66% ROE. Revenue growth accelerated to $7.08 billion in 2025, with net income reaching $743 million. Analyst sentiment remains positive with a $445.71 consensus price target, though technical indicators suggest near-term resistance at $386.
The outlook for RL is favorable given consistent earnings outperformance and brand strength in key markets like Asia. Risks include premium valuation multiples and macroeconomic pressures on consumer spending. Wall Street maintains a bullish stance with 66% of analysts rating it a Buy, projecting 16% upside from current levels based on continued digital and direct-to-consumer expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
